Literature DB >> 28864253

Engineered Potato virus X nanoparticles support hydroxyapatite nucleation for improved bone tissue replacement.

Ines Lauria1, Christina Dickmeis2, Juliane Röder3, Malin Beckers4, Stephan Rütten5, Ying Ying Lin6, Ulrich Commandeur7, Horst Fischer8.   

Abstract

Bionanoparticles based on filamentous phages or flexuous viruses are interesting candidates for meeting the challenges of tailoring biomineralization in hydrogel-based bone tissue substitutes. We hypothesized that hydroxyapatite crystal nucleation and matrix mineralization can be significantly increased by mineralization-inducing (MIP) and integrin binding motif (RGD) peptides presented on biomimetic nanoparticles. In this study, Potato virus X (PVX), a flexible rod-shaped plant virus was genetically engineered to present these functional peptides on its particle surface. Recombinant PVX-MIP/RGD particles were isolated from infected Nicotiana benthamiana plants and characterized by western blot, SEM, TEM, and TPLSM in MSC cultures. The presence of RGD was proven by cell attachment, spreading, and vinculin cluster analysis, and MIP by in vitro mineralization and osteogenic differentiation assays. Thus the tailored surface of genetically engineered PVX forms fibril-like nanostructures which enables enhanced focal adhesion-dependent cell adhesion, and matrix mineralization verified by Alizarin. Hydroxyapatite crystal nucleation is supported on recombinant PVX particles leading to a biomimetic network and bundle-like structures similar to mineralized collagen fibrils. In conclusion, the recombinant flexuous PVX nanoparticles exhibit properties with great potential for bone tissue substitutes. STATEMENT OF SIGNIFICANCE: A suitable biomaterial for tissue engineering should be able to mimic the endogenous extracellular matrix by presenting biochemical and biophysical cues. Novel hydrogel-based materials seek to meet the criteria of cytocompatibility, biodegradability, printability, and crosslinkability under mild conditions. However, a majority of existing hydrogels lack cell-interactive motifs, which are crucial to modulate cellular responses. The incorporation of the plant virus PVX to the hydrogel could improve functions like integrin-binding and mineralization due to peptide-presentation on the particle surface. The tailored surface of genetically engineered PVX forms fibril-like nanostructures which enables enhanced focal adhesion-dependent cell adhesion and matrix mineralization and offers great potential for the development of new hydrogel compositions for bone tissue substitutes.
Copyright © 2017 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hydroxyapatite nucleation; Nanoparticles; Osteogenic differentiation; Plant viruses; Stem cells

Mesh:

Substances:

Year:  2017        PMID: 28864253     DOI: 10.1016/j.actbio.2017.08.039

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  4 in total

1.  Tobacco Mosaic Viral Nanoparticle Inhibited Osteoclastogenesis Through Inhibiting mTOR/AKT Signaling.

Authors:  Zhongshu Shan; Hongtao Bi; Angxiu Suonan; Yong Gu; Huan Zhou; Kun Xi; Rui Xiong; Hua Chen; Liang Chen
Journal:  Int J Nanomedicine       Date:  2020-09-29

Review 2.  Repurposing Plant Virus Nanoparticles.

Authors:  Kathleen L Hefferon
Journal:  Vaccines (Basel)       Date:  2018-02-14

Review 3.  Small, Smaller, Nano: New Applications for Potato Virus X in Nanotechnology.

Authors:  Juliane Röder; Christina Dickmeis; Ulrich Commandeur
Journal:  Front Plant Sci       Date:  2019-02-19       Impact factor: 5.753

4.  Gelatin-methacryloyl hydrogels containing turnip mosaic virus for fabrication of nanostructured materials for tissue engineering.

Authors:  Ivonne González-Gamboa; Edith Velázquez-Lam; Matías José Lobo-Zegers; Ada Itzel Frías-Sánchez; Jorge Alfonso Tavares-Negrete; Andrea Monroy-Borrego; Jorge Luis Menchaca-Arrendondo; Laura Williams; Pablo Lunello; Fernando Ponz; Mario Moisés Alvarez; Grissel Trujillo-de Santiago
Journal:  Front Bioeng Biotechnol       Date:  2022-09-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.